N	Concordance
1	ased GVHD. The use of NK cells as an adoptive immunotherapy after BMT is at
2	cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced 
3	 IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective le
4	                     Intraperitoneal adoptive immunotherapy of ovarian carc
5	 the relative therapeutic benefit of adoptive immunotherapy as an adjuvant 
6	oxicity and therapeutic potential of adoptive immunotherapy  with Epstein-B
7	ration. The roles of chemotherapy or adoptive immunotherapy in combination 
8	 cytotoxicity in patients receiving  adoptive immunotherapy with EBV-specif
9	stress on the efficacy of anti-viral adoptive immunotherapy in an immunocom
10	t be suitable for clinical trials of adoptive-immunotherapy, especially in 
11	ard to chronic infection, memory and adoptive immunotherapy.               
12	idered as candidates for pre-emptive adoptive immunotherapy.               
13	nd IL-2-mediated tumor regression in adoptive immunotherapy. In this study,
14	s results in an enhanced response to adoptive immunotherapy. We undertook t